ISSN:
1432-0851
Keywords:
Key words Tumor antigen presentation
;
Immunotherapy
;
MHC class II
;
Cross-priming
;
Cell-based cancer vaccines
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Cell-based tumor vaccines have been developed on the basis of the hypothesis that tumor cells can be genetically modified to present antigen to T lymphocytes directly. Contrary to expectations, cross-priming is the predominant pathway for activation of tumor-specific CD8+ T cells, while direct presentation of antigen dominates activation of tumor-specific CD4+ T cells. These results pose interesting paradoxes for the generation of immune responses, and have definite implications for the development of anti-cancer vaccines.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s002620050463
Permalink
